西酞普兰联合小剂量阿立哌唑治疗躯体形式障碍的临床分析

Clinical analysis of treating somatoform disorders by citalopram hydrobromide combined with small dosage of aripiprazole.

目的探讨西酞普兰联合小剂量阿立哌唑治疗躯体形式障碍的疗效。方法将40例服用西酞普兰联合小剂量阿立哌唑患者(简称研究组)与38例单用西酞普兰(简称对照组),从药物的起效时间、症状的改善时间,治疗2、4及6周时SCL-90各因子分、TESS分值,治疗后3个月内服药的依从性及症状的复燃率,以及缓解期采用功能失调性态度问卷(DAS)对两组患者缓解期认知功能进行评定。结果研究组在起效与症状改善时间上均较对照组快;治疗2、4周时两组在躯体化、焦虑、抑郁及偏执分值上有显著差异,而治疗6周时SCL-90除偏执因子分外,两组比较无显著差异;两组在不良反应方面无显著差异,但在治疗的依从性上,研究组能够认识自己疾病并坚持服药的例数却明显高于对照组;研究组3个月内症状的复燃率明显低于对照组;缓解期认知功能比较,研究组DAS评分较对照组明显降低。结论西酞普兰联合小剂量阿立哌唑治疗躯体形式障碍的疗效较单用前者更佳。

Objective To explore the efficacy of somatoform disorders by citalopram hydrobromide combined with small dosage of aripiprazole. Method 40 patients take citalopram hydrobromide combined with small dosage of aripiprazole are defined as the study group and 38 patients take eitalopram hydrobromide are defined as the control group. The time of efficacy and improvement, SCL -90 scores after 2,4,6 weeks, TESS scores, compliance and relapse of symptoms in 3 months treatment,cognition function tested by DAS in remission are evaluated and compared in two groups. Results The time of efficacy and improvement was shorter in study group than in control group. Compared with factors of SCL - 90 in two groups after 4,6 weeks treatment, the significant difference was observed in scores of somatoform, anxiety, depression, paranoid. There was no significant difference in factors of SCL - 90 except paranoid after 6 weeks treatment. No significant difference of side - effects was observed, but the number of good compliance patients who have insight and insisted on taking medicines was more in study group than that in control group. The relapse of symptoms in the study group was much lower than the control group. The scores of DAS during remission in study group were obviously lower than in control group. Conclusion It was indicated that the efficacy to choice of eitalopram hydrobromide combined with small dosage of aripiprazole could be better than citalopram only when treating clinically somatoform disorders.